<DOC>
	<DOC>NCT00086086</DOC>
	<brief_summary>The purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia.</brief_summary>
	<brief_title>Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) &amp; Anemia</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Symptomatic CHF for at least 3 months Reduced left ventricular ejection fraction Stable heart failure medication Hemoglobin concentration between 9.0 and 12.5 g/dL Hypertension Unstable angina pectoris or recent myocardial infarction Likely to receive cardiac transplant Major organ transplant (e.g., lung, liver, heart) or in renal replacement therapy (e.g., dialysis) Recent or current treatment for malignancy Systemic hematologic disease Anemia due to acute or chronic bleeding Recent EpogenÂ® or darbepoetin alfa therapy Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Symptomatic Congestive Heart Failure</keyword>
	<keyword>CHF</keyword>
	<keyword>Anaemia</keyword>
	<keyword>Anemia</keyword>
</DOC>